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Microparticles (MPs) are small membrane vesicles that are released from many different cell types by exocytic
budding of the plasma membrane in response to cellular activation or apoptosis. MPs may also be involved in
clinical diseases because they express phospholipids, which function as procoagulants. Although flow cytometry is
the most widely used method for studying MPs, some novel assays, such as tissue factor-dependent procoagulant
assay or the ELISA method, have been reported. However, the use of quantification of MP as a clinical tool is still
controversial. Elevated platelet-derived MP, endothelial cell-derived MP, and monocyte-derived MP concentrations
are documented in almost all thrombotic diseases occurring in venous and arterial beds. However, the significance
of MPs in various clinical conditions remains controversial. An example of this controversy is that it is unknown if
MPs found in peripheral blood vessels cause thrombosis or whether they are the result of thrombosis. Numerous
studies have shown that not only the quantity, but also the cellular origin and composition of circulating MPs, are
dependent on the type of disease, the disease state, and medical treatment. Additionally, many different functions
have been attributed to MPs. Therefore, the number and type of clinical disorders associated with elevated MPs are
currently increasing. However, MPs were initially thought to be small particles with procoagulant activity. Taken
together, our review suggests that MPs may be a useful biomarker to identify thrombosis.
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Microparticles (MPs) are small membrane vesicles that
are released from many different cell types by exocytic
budding of the plasma membrane in response to cellular
activation or apoptosis [1-3]. MPs disseminate various bio-
active effectors originating from the parent cells. There-
fore, MPs can alter vascular function and may induce
biological responses involved in vascular homeostasis [4].
Although most MPs in human blood originate from plate-
lets, MPs are also released from leukocytes, erythrocytes,
endothelial cells, smooth muscle cells (SMCs), and cancer
cells [5-10]. MP concentrations are documented in almost
all thrombotic diseases occurring in venous and arterial
beds [11-14]. Elevated levels of MPs have also been found
in a number of conditions associated with inflammation,
cellular activation and dysfunction, angiogenesis, and
transport [15-23]. In this review, we address the function* Correspondence: shosaku-n@mbp.ocn.ne.jp
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article, unless otherwise stated.of MPs and some of the clinical findings that suggest im-
portant roles for procoagulant MPs.Review
Composition and production of MPs
The standard platelet-derived MP (PDMP) measurement
by flow cytometry was demonstrated by the Inter-
national Society of Thrombosis and Haemostasis [24,25].
According to this committee, MPs can range in size
from 0.1 to 1.0 μm. The membrane composition of MPs
reflects the membranous elements of the cell of origin
(Table 1). PDMPs contain molecules in addition to gly-
coproteins (GPs), such as platelet-activating factor, β-
amyloid precursor protein, Ca2+-dependent protease
calpain, arachidonic acid, and many phospholipids
[26-31]. Phospholipids are particularly important because
they are involved in the function of PDMPs. Furthermore,
PDMPs serve as a finely tuned transcellular delivery sys-
tem for the chemokine regulated on activation, normal T-
cell expressed and secreted (RANTES) [32].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Origin and antigens of MPs
Origin Antigen
Erythrocyte CD235a (glycophorin A)
Platelet CD42a (GPIX)
CD42b (GPIb)





Monocyte CD14 (endotoxin receptor)
Lymphocyte CD4, CD8, CD20
Endothelial cell CD31 (PECAM-8)
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pholipids, cytoplasmic components, and various antigens
that are characteristic of the state of the cell from which
they originated and also of the type of stimulus [33,34].
Some studies have analyzed the proteome of MPs and
identified hundreds of proteins [35,36]. Proteins fromFigure 1 Mechanisms participating in the regulation of transmembra
followed by PDMP shedding. Phospholipid asymmetry is under the cont
Following cellular activation, calcium is released from the endoplasmic reti
activation of calpain. PC, phosphatidylcholine; SM, sphingomyeline; PEa, phMPs may be useful biomarkers for various disease pro-
cesses [36].
MPs are constitutively released from the surface of
cells, but their formation can be upregulated by cellular
activation or apoptosis [37,38]. After cellular activation
or apoptosis is triggered, there is a rise in cytosolic
calcium concentrations followed by cytoskeletal changes.
Many studies have shown that calpain activation is
important for PDMP generation [39,40]. Additionally,
calpain appears to help limit phosphatidyl inositol phos-
phate (PIP)2 formation following platelet activation, and
PIP2 content is an important determinant of PDMP for-
mation [41,42]. However, some reports have suggested
the existence of a distinct mechanism of calpain activa-
tion [43,44]. Plasma membranes of cells contain different
types of phospholipids. Although uncharged phospho-
lipids are mainly present in the outer leaflet of the mem-
brane bilayer, the inner leaflet contains negatively
charged aminophospholipids, such as phosphatidylserine
(PS). During activation or apoptosis of the cell, there is a
change in the membrane with alteration in the normal
lipid bilayer, ‘flip-flopping’ the internal PS to the external
surface. As a result, PS-exposing MPs may be released
from cells (Figure 1) [45].
High shear stress can initiate platelet aggregation and
shedding of procoagulant-containing PDMPs [46]. Chow
et al. [47] suggested that thrombin that is formed in the
vicinity of primary hemostatic plugs in areas of elevated
shear stress plays a major role in the propagation of thrombine migration of phosphatidylserine (PS) in activated platelets,
rol of active flippase, while floppase and scramblase remain inactive.
culum, which can lead to the loss of phospholipid asymmetry and
osphatidylethanolamine.
Nomura and Shimizu Journal of Intensive Care  (2015) 3:2 Page 3 of 11by potentiating shear-induced PDMP generation. Further-
more, platelet GPs and specific receptors can be involved in
high shear stress-induced PDMP formation [46,48-50].
Miyazaki et al. [46] examined the mechanisms involved in
PDMP production induced by high shear stress and showed
that binding of von Willebrand factor to GPIb, influx of
extracellular calcium, and activation of platelet calpain were
required to generate PDMPs under conditions of high shear
stress. In addition, Reininger et al. [50] recently reported that
the GPIb receptor mediates adhesion to von Willebrand fac-
tor, and under hydrodynamic flow, stretching of the platelet
membrane occurs, followed by separation of areas of teth-
ered membranes and production of MPs. Shear stress is also
involved in the mechanism of PDMP generation because it
is a major determination of endothelial apoptosis [51,52].
MPs are similar to damage-associated molecular patterns
(DAMPs). DAMPs are normally hidden within live cells and
are released from dying or damaged cells [53]. The typical
DAMPs are a high mobility group box 1 (HMGB1)[54].
HMGB1 is normally located in the nucleus where it acts as
a DNA chaperon by regulating transcription [55]. However,
the extracellular HMGB1 is a substance itself and works tis-
sue injuriously for normal cell or organ [56]. In contrast, the
role of MPs is a carrying system of tissue factor (TF), cell ad-
hesion molecules, chemokines, and HMGB1 [56,57]. How-
ever, the differences between MPs and DAMPs are actually
confused.
Effective roles of MPs for coagulation
MPs were initially thought to be related to disease because
they express phospholipids, which are procoagulants.
These MPs support generation of thrombin and could be
involved in diffuse intravascular coagulation occurring in
disease states. However, such a coagulation system is acti-
vated not only in disease states, but also in healthy indi-
viduals. Berckmans et al. [58] reported that MPs circulate
in healthy humans and support low-grade thrombin gen-
eration. Sinauridze et al. [59] reported that PDMPs have
50- to 100-fold higher specific procoagulant activity than
activated platelets. Exposure of PS not only facilitates for-
mation of coagulation complexes, but also promotes the
ability of TF to initiate coagulation [60].
MPs support coagulation by factor (F)VII/TF-dependent
and independent pathways [61]. During vascular damage,
blood contacts extravascular TF, resulting in extrinsic co-
agulation activation and formation of fibrin. Indeed, TF
can become active upon adhesion and fusion of MPs to
activated platelets.
Several studies found that stimulation by tumor
necrosis factor (TNF)-α, lipopolysaccharide, or oxidized
low-density lipoprotein in cultured human umbilical
vein endothelial cells results in an increase in the release
of endothelial cell-derived MPs (EDMPs) expressing surface
TF [7,62,63]. The addition of increasing concentrations ofthese EDMPs to a coagulation assay shortens the plasma
clotting time. This effect is not observed in FVII-deficient
plasma, indicating that procoagulant activity of EDMPs is
FVII/TF dependent in this situation. Interestingly, a subset
of EDMPs bearing von Willebrand factor appears to be able
to induce platelet aggregation [64].
Monocyte-derived MPs (MDMPs) also contribute to
the development of platelets and fibrin-rich thrombus
at sites of vascular injury, through the recruitment of
cells and accumulation of TF. MDMPs express the P-
selectin glycoprotein ligand-1 and TF [65]. The binding
of these MDMPs to P-selectin on activated endothelial
cells on activated platelets within the developing
thrombus may promote accumulation of TF and local-
ized thrombin generation. TF-exposing monocytes may
also release TF-exposing MDMPs [66]. Subsequently,
activated platelets expose P-selectin and are capable of
capturing TF-exposing MDMPs via P-selectin glycopro-
tein ligand-1. Consequently, MP-associated TF becomes
rapidly deposited at the site of the developing thrombus.
DelConde et al. [67] showed in vitro that fusion of
membranes of TF-exposing MPs and activated platelets
results in the transfer of TF in platelet membranes. This
fusion results in co-localization of TF and coagulation
factors, thereby promoting a more efficient initiation
and propagation of coagulation.
At the MP surface, the presence of proteins inhibiting
coagulation, such as TF pathway inhibitor, protein C, or
thrombomodulin, raises the possibility of eventual con-
tribution of MPs to an anticoagulant pathway [68,69].
While TF is exposed by EDMPs, TF activity is markedly
inhibited by MP-associated tissue factor pathway inhibi-
tor (TFPI). In storage-induced PDMPs, 10% of which
contain TF, TF-dependent thrombin generation can
only be observed in plasma in which TFPI is neutralized
[70]. A balance between TF and TFPI at the MP surface
is likely to be a crucial feature in the initiation of blood
coagulation, and higher levels of MPs containing TF
possibly overcome the TFPI anticoagulant pathway [68].
The effect of activated protein C, which has anticoagu-
lant and anti-inflammatory properties, on endothelial
cells and EDMP formation has also been studied [69].
Cultured endothelial cells exposed to activated protein
C release EDMP with membrane-bound endothelial
protein C receptor. Activated protein C that is bound to
this receptor retains its anticoagulant activity in redu-
cing formation of thrombin [69]. Other mechanisms
contributing to the regulation of MP procoagulant
properties rely on the balance between TNF-α and
anti-inflammatory cytokines, such as interleukin (IL)-
10. Indeed, endogenous IL-10 was recently reported
to downregulate TF expression in monocytes and TF-
bound MDMP release, impeding generation of throm-
bin [71].
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MPs contain antigens of their cell of origin and can trans-
fer these surface molecules to other cell types and organs
[72-74]. These carrier vesicles contain material from the
lumen of the donor compartment and expose the cyto-
plasmic side of this compartment at their outer surface,
such as exosomes and ectosomes (Figure 2). The binding
of MP surface antigens to their specific counter receptor
may activate intracellular signaling pathways. PDMPs
show transcellular delivery of unmetabolized arachidonic
acid. Additionally, PDMP activation of human vascular
endothelial cells and U-937 cells induces de novo expres-
sion of cyclooxygenase-2 but not cyclooxygenase-1 [30].
The concentrated delivery of PDMP bioactive lipids
may modulate multicellular interactions that occur in
the early stages of atherogenesis. Nomura et al. [75] also
reported that PDMPs that are induced by high shear
stress enhance expression of cell adhesion molecules by
THP-1 and endothelial cells. PDMPs may contribute to
the development of adhesion and participate in vascular
damage that is observed in inflammatory disorders. Add-
itionally, PDMPs may possess high mobility and accessi-
bility to leukocytes [76].
Identification of MPs in the clinical setting
An identification method for MPs is important for clinical
studies on MPs. Appropriate sampling conditions, pro-
cessing, and storage of samples are essential [1]. MPs can
be directly quantified in platelet-poor plasma, obtained by
serial centrifugation of citrated whole blood. Alternatively,Figure 2 Different types of secreted membrane microparticles.
Microparticles or pre-microparticles originally exist in multivesicular
bodies. Following cellular activation, multivesicular bodies move
close to the cellular membrane. Microparticles that are generated in
multivesicular bodies are called exosomes once they are secreted.
Secreted vesicles can form inside internal compartments from where
they are subsequently secreted by fusion of these compartments
with the plasma membrane. This microparticle is called an ectosome.
Active calpain cleaves the cytoskeleton, leading to the formation of
a membrane bleb and ectosome release. Exosome functionates by
delivery system of some cellular substances. Ectosome possesses a
procoagulant activity.washed MPs can be isolated from platelet-poor plasma by
ultracentrifugation before resuspension and analysis.
The most widely used method for studying MPs is
flow cytometry because of its simplicity and the wealth
of information that can be obtained from the population
under study [77]. Platelet-poor plasma or MP suspen-
sions are labeled with fluorescently conjugated monoclo-
nal antibodies. The major advantage of flow cytometry is
double staining of MPs to determine the origin/cellular
source of MPs. Annexin V binding is used to confirm
the phospholipid properties of MPs, although most
endothelial MPs do not express this antigen. Antibodies
to specific surface antigens expressed on the cells of ori-
gin are used to identify the subtype of MP (e.g., anti-
GPIb for identification of PDMP). Flow cytometry also
allows the criterion of size to be applied to MP analysis,
by assessment of the forward light scatter of MPs. The
identification of events of a specified size is most accur-
ately performed using calibration beads of a known
diameter for comparison [1,26]. Additionally, a variety of
cell-specific antibodies have been used, and the specifi-
city that is chosen is likely to influence the results. An
example of this situation is that αIIbβ3 and P-selectin are
both platelet-specific antigens but αIIbβ3 is present on all
platelets, while P-selectin is only found on activated
platelets.
The enzyme-linked immunosorbent assay (ELISA)
method is an easier and reproducible PDMP assay [78,79].
When using ELISA techniques, PDMPs may be quanti-
tated with reference to a standard curve. This method will
hopefully contribute toward the understanding of partici-
pation of PDMPs in the clinical setting, if antibodies that
are reactive with platelet activation markers, such as P-
selectin and soluble CD40 ligand, are used. One of the
problems of the ELISA method is the possibility that it
contains soluble GPs, such as the GPIb/IX/V complex.
Ueba et al. [80-83] measured circulating PDMPs in
healthy Japanese individuals using the ELISA method and
suggested that PDMPs were positively associated with the
level of metabolic syndrome. The use of MP quantification
as a clinical tool is still debatable. A large-scale clinical
trial for various thrombotic diseases using ELISA kits was
performed in Japan [84].
Atherothrombosis and MPs
Production of PDMPs, EDMPs, and leukocyte-derived
MPs can be increased by inflammatory conditions [85,86].
MPs formed by in vivo stimulation with a chemotactic
peptide in healthy volunteers were able to induce IL-6 and
monocyte chemoattractant protein (MCP)-1 release, as
well as TF expression, by endothelial cells in vitro. The
addition of neutrophils to cultured endothelial cells in-
duces the release of IL-6 and IL-8. This effect can be repli-
cated by cell-free supernatant or purified MPs, but not
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osis is adhesion of monocytes to endothelial cells, followed
by subendothelial transmigration. Cytokines, such as IL-
1β and TNF-α, affect this process by inducing synthesis or
upregulation of leukocyte-endothelial adhesion molecules.
In vitro stimulation of monocytes and endothelial cells by
high shear stress-induced PDMPs results in significantly
increased production of Il-8, IL-1β, and TNF-α [70]. Fur-
thermore, treatment of endothelial cells and monocytes
with PDMPs prior to co-incubation modulates monocyte-
endothelial cell interactions, by increasing the expression
of adhesion molecules on both cell types [70].
Circulating MPs of platelet and leukocytic origins
promotes recruitment of inflammatory cells and induces
cellular adhesiveness through upregulation of cytokines and
cytoadhesions in endothelial cells and monocytes [87].
At high shear stress, PDMP rolling enables delivery of
RANTES to inflamed endothelium, thus favoring adhesion
of monocytes and infiltration of plaques [32]. Development
and progression of atherosclerotic plaques are associated
with apoptotic cell death, explaining the presence of a con-
siderable amount of procoagulant MPs within plaques [9].
Furthermore, enhanced apoptosis or activation of leuko-
cytes, SMCs, and endothelium contribute to accumulation
of MPs [9,88]. Compared with their circulating counterpart,
MPs trapped within the plaque are present at much higher
concentrations and display higher thrombogenic potential.
In plaques, most of these MPs are from activated leukocytes,
a hallmark of inflammation, and from erythrocytes, indicat-
ing occurrence of intraplaque hemorrhage, which is a
marker of vulnerability of plaques [88]. Atherosclerotic pla-
ques also contain a considerable amount of SMC-derived
MPs and EDMPs [9]. Beyond the contribution of MPs to
plaque thrombogenicity, MPs can also contribute to instabil-
ity by mediating the recruitment of inflammatory cells.
Therefore, circulating MPs can result in vascular inflamma-
tion, endothelial dysfunction, leukocyte adhesion, and
recruitment. This could contribute to plaque growth or
stent-induced vascular inflammation because MPs convey
biological effectors [89].
Thrombocytopenia
Some anti-platelet antibodies can induce complement-
mediated formation of PDMPs and initiate platelet destruc-
tion [90,91]. Antiphospholipid antibodies are found in
antiphospholipid antibody syndrome (APS). These anti-
bodies are directed against plasma proteins, including
β2GPI and prothrombin, which are bound to anionic phos-
pholipids. These phospholipids are abundant on activated
platelets, apoptotic cells, and MPs. MP levels are elevated in
patients with APS, but not thrombosis, compared with
healthy controls [1,92]. Production of procoagulant MPs in
APS patients may represent a new pathogenic mechanism
for the thrombotic complications of this disease [7,93].Galli et al. [94] performed a study of PDMPs in throm-
botic thrombocytopenic purpura (TTP) and found a rise
and fall in PDMP levels with the course of the disease,
suggesting that PDMPs are clinically relevant. Jimenez
et al. [95] studied the effect of plasma from patients with
acute TTP on cultured brain and renal microvascular
endothelial cell lines. They found a 5- to 6-fold increase in
EDMP generation with TTP plasma compared with con-
trols. Nomura et al. [96] investigated MP levels in patients
following allogeneic stem cell transplantation where
transplant-related complications included vascular disor-
ders, such as veno-occlusive disease, pulmonary vasculop-
athy, and thrombotic microangiopathy (TMA). Although
only one of the 21 patients who were studied developed
TMA/TTP, a continuous rise in platelets, EDMPs, and
MDMPs was observed in all of the patients, for up to
4 weeks following transplantation. These findings paral-
leled an increase in soluble endothelial markers, including
vascular cell adhesion molecule (VCAM)-1 and E-selectin.
Cardiovascular diseases
Procoagulant MPs, and especially EDMP, are elevated in
patients with acute coronary syndrome compared with pa-
tients with stable anginal symptoms or controls [97]. This
finding reflects the degree of acute vascular injury and in-
flammation at the time of measurement. Steppich et al.
[63] reported that in acute myocardial infarction, MPs
may also have an anticoagulant function through expres-
sion of TFPI and reduction of TF-dependent thrombin
generation, which may help limit thrombus formation.
Furthermore, EDMP levels are higher in high-risk coron-
ary lesions compared with low-risk lesions [98].
A number of cytokines can induce procoagulant activity
in leukocytes [99]. A proinflammatory member of the C-C
chemokine family, RANTES, is a potent chemoattractant
of memory T lymphocytes, monocytes, eosinophils, and
basophils. Several previous studies have suggested that
RANTES is an inflammatory mediator in cardiovascular
disease [11,85,100]. Additionally, the presence of RANTES
may predict restenosis after percutaneous coronary inter-
vention in patients with stable angina [101,102]. PDMPs
also relate to the levels of RANTES [11,32,79] and are as-
sociated with atherosclerotic events after percutaneous
coronary intervention [103].
Diabetes mellitus
A few studies on the potential role of PDMPs in diabetic
complications have been reported [104-106]. MPs are ele-
vated in diabetic patients. However, studies have found
differences in the MP profile in relation to the disease type
and the presence or absence of MPs. Sabatier et al. [107]
reported that in type 1 diabetes, the procoagulant poten-
tial of MPs, as measured by a prothrombinase assay, was
elevated and correlated with the degree of glycemic
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though total numbers of MPs were elevated in type 2 dia-
betes, there was no associated increase in their
procoagulant potential. Levels of PDMPs and MDMPs are
correlated with diabetic complications or the extent of
diabetic retinopathy, which is associated with microvascu-
lar damage [108-114]. Elevated EDMP levels are predictive
for the presence of coronary artery lesions, and they are a
more significant independent risk factor than the length
of diabetic disease, lipid levels, or presence of hyperten-
sion [115]. Interestingly, elevated EDMP levels are predict-
ive in identifying a subpopulation of diabetic patients
without typical anginal symptoms who have angiographic
evidence of coronary artery disease. Production of PDMP,
MDMP, and EDMP can be increased in type 2 diabetes.
These MPs contribute to the generation of atherothrom-
bosis in type 2 diabetes (Figure 3).
Sepsis and disseminated intravascular coagulation
Disseminated intravascular coagulation (DIC) is frequently
complicated by various diseases [116]. CoagulationFigure 3 Role of MPs in type 2 diabetes into atherosclerosis and thro
in type 2 diabetes. These MPs contribute to the generation of atherothrom
(CD11b/CD18), ICAM-1: intercellular adhesion molecule-1, VCAM-1: vascularabnormalities and thrombocytopenia are common in
DIC, and the extent of hemostatic disorders appears to
correlate with disease severity. In particular, septic
shock-induced DIC contributes to multiple organ fail-
ure. In DIC patients, thrombin generation may react
with thrombin receptors located on platelets and results
in the generation of PDMPs by activation of platelets.
Additionally, HMGB1 also plays a role in the pathogen-
esis of DIC because plasma HMGB1 levels correlate
with the DIC score [117]. Nomura et al. [118] described
the role of PDMPs and HMGB1 in DIC patients with
hematological malignancies.
Activation of leukocytes and endothelial cells are also
observed in DIC. These contribute to the generation of
EDMPs, MDMPs, and others. Delabranche et al. [119]
reported that EDMPs are relevant biomarkers of septic
shock-induced DIC and can be used to evaluate early
vascular injury. Furthermore, Hellum et al. [120] re-
cently reported that MPs that were obtained from pa-
tients with meningococcal septic shock displayed more
efficient TF-dependent thrombin generation and clotmbosis. Production of PDMPs, MDMPs, and EDMPs can be increased
bosis in type 2 diabetes. Mac-1: β-2 integrin family in monocyte
cell adhesion molecule-1.
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They concluded that MP-associated TF activity was
closely associated with plasma lipopolysaccharide levels
in the septic shock group. These changes are thought to
be dependent on TF on MPs (Figure 4).
Other clinical situations
Elevated PDMP levels have been detected in other clinical
conditions, including infectious diseases [121,122], periph-
eral blood stem cell harvest [123-125], progressive systemic
sclerosis [126], and arteriosclerosis obliterans [127,128].
Additionally, PDMPs are used for monitoring of anti-
thrombotic therapy [110,129].
PDMPs bind to hematopoietic cells, resulting in en-
hancement of their engraftment by stimulating prolifera-
tion, survival, adhesion, and chemotaxis [130-132]. Majka
et al. [133] also reported that PDMPs transfer platelet-
specific immunoreactive antigens to the surface of endo-
thelial and hematopoietic cells. Another study showed that
endothelial progenitor cell-derived MPs were incorporated
in endothelial cells by interaction with α4 and β1 integrins
expressed on the MP surface [134]. This finding suggested
that endothelial progenitor cells may activate angiogenesis
in endothelial cells by releasing MPs able to trigger an
angiogenic program. CD42b-negative/α4-integrin-positive
MPs show the same changes as stroma cell-derived factor
1 and soluble CD40 ligand, with an increase in CD34+
stem cells during peripheral blood stem cell harvest [118].
Janowska-Wieczorek et al. [135] suggested that MPs that
are actively released from cells may play an important role
in cell-to-cell communication. Results from other studies
have also supported this view [124,134,136]. Furthermore,
elevation of EDMPs in patients following allogeneic stem
cell transplantation may be associated with some transplant-
related complications, such as graft-versus-host-disease
(GVHD) and TMA [96,125,131].
In lung cancer patients, PDMPs induce metastasis and
angiogenesis, [135] and MDMPs may be a sign of vascularFigure 4 Role of TF on MPs in activation of target cells. MPs can
carry some substances, such as integrin, cell adhesion molecule,
chemokines, phospholipids, and TF. TF mainly contributes to
activation of the extrinsic coagulation system. PS, phosphatidylserine;
CAM, cell adhesion molecule.complications [137]. In patients with various types of can-
cer, PDMPs possess CXCR4 and contribute to chemotaxis
by stromal cell-derived factor 1, resulting in progression
or metastasis of cancer [138,139]. TF overexpression by
cancer cells is closely associated with tumor progression,
and TF-expressing MPs that are shed by cancer cells are
linked to the genetic status of cancer [140-144].
A current feature of clinical applications regarding
MPs is detection of TF-expressing MPs that are gener-
ated by apoptosis. Fas ligand- or TNF-related apoptosis-
inducing ligand-positive MPs have been isolated from
sera of patients with cancer, and these MPs can induce
T-cell apoptosis [145-147]. The pattern of procoagulant
MPs that are released during acute allograft rejection
suggests endothelial cell activation and Fas-mediated
apoptosis [148]. Procoagulant MPs in pulmonary arterial
hypertension also belong to apoptotic EDMPs [149].
Conclusion
We have summarized the literature to date that is relevant
to MPs, including a growing list of clinical disorders that
are associated with elevated MP levels. MPs were initially
thought to be small particles with procoagulant activity.
However, the possibility that MPs evoke cellular responses
in the immediate microenvironments where they are
formed is now under investigation.
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